Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.32 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.32 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.32 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.32 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3031807 | 0.91 | FFAR2 (0.31) | FFAR2EZH2 | |
| SCHEMBL3024056 | 0.89 | NPC1 (0.35) | FFAR2EZH2TIPARP | |
| SCHEMBL3019933 | 0.88 | EZH2 (0.33) | FFAR2GABRA1GABRR1GABRA5GABRB2 | |
| SCHEMBL3020643 | 0.88 | EZH2 (0.33) | FFAR2GABRA1GABRR1GABRA5GABRB2 | |
| SCHEMBL3415049 | 0.87 | GABRA1 (0.31) | GABRA1GABRR1GABRA5GABRB2GABRA4 | |
| SCHEMBL3019837 | 0.87 | GABRA1 (0.31) | GABRA1GABRR1GABRA5GABRB2GABRA4 | |
| SCHEMBL3029302 | 0.87 | PYGL (0.34) | FFAR2GABRA1GABRR1GABRA5GABRB2 | |
| SCHEMBL3023982 | 0.86 | FFAR2 (0.33) | FFAR2 | |
| SCHEMBL3005356 | 0.85 | CSF1R (0.33) | FFAR2EZH2 | |
| SCHEMBL3057369 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349885-B2 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect | LG LIFE SCIENCES LTD. (KR) | 2013-01-08 | — | — | US | claimed |
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG CHEM, LTD. (KR) | 2012-10-25 | — | — | US | claimed |
| US-20100210647-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2010-08-19 | — | — | US | claimed |
| EP-2178869-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG Life Sciences Ltd. (KR) | 2010-04-28 | — | — | EP | claimed |
| WO-2009025477-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2009-02-26 | — | — | WO | claimed |
| US-8889691-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2014-11-18 | — | — | US | disclosed |
| US-20140024618-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2014-01-23 | — | — | US | disclosed |
| EP-2230238-B1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD (KR) | 2013-12-11 | — | — | EP | disclosed |
| US-8569307-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2013-10-29 | — | — | US | disclosed |
| US-8349885-B2 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect | LG LIFE SCIENCES LTD. (KR) | 2013-01-08 | — | — | US | disclosed |
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG CHEM, LTD. (KR) | 2012-10-25 | — | — | US | disclosed |
| US-20120252798-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG CHEM, LTD. (KR) | 2012-10-04 | — | — | US | disclosed |
| US-8222414-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2012-07-17 | — | — | US | disclosed |
| EP-2230238-A2 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG Life Sciences Ltd. (KR) | 2010-09-22 | — | — | EP | disclosed |
| US-20100210647-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2010-08-19 | — | — | US | disclosed |
| EP-2178869-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG Life Sciences Ltd. (KR) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009025477-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252798-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, TNF | FFAR2 2124/4885GABRA1 4804/4885GABRR1 4421/4885 |
| US-20140024618-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, TNF | FFAR2 2124/4885GABRA1 4804/4885GABRR1 4421/4885 |
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | IDO1, IDO2, INMT | FFAR2 2822/4885GABRA1 3393/4885GABRR1 2304/4885 |
| US-20100210647-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, TNF | FFAR2 2124/4885GABRA1 4804/4885GABRR1 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.